Mutual of America Capital Management LLC Has $52,000 Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

view original post

Mutual of America Capital Management LLC raised its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIPGet Rating) by 23.9% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 1,833 shares of the specialty pharmaceutical company’s stock after acquiring an additional 354 shares during the period. Mutual of America Capital Management LLC’s holdings in ANI Pharmaceuticals were worth $52,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Emerald Mutual Fund Advisers Trust grew its holdings in ANI Pharmaceuticals by 234.7% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 299,493 shares of the specialty pharmaceutical company’s stock valued at $8,419,000 after buying an additional 210,002 shares during the last quarter. Emerald Advisers LLC lifted its position in shares of ANI Pharmaceuticals by 326.8% in the 1st quarter. Emerald Advisers LLC now owns 354,045 shares of the specialty pharmaceutical company’s stock worth $9,952,000 after acquiring an additional 271,101 shares during the period. Comerica Bank lifted its position in shares of ANI Pharmaceuticals by 31.1% in the 1st quarter. Comerica Bank now owns 11,195 shares of the specialty pharmaceutical company’s stock worth $367,000 after acquiring an additional 2,655 shares during the period. Thompson Siegel & Walmsley LLC lifted its position in shares of ANI Pharmaceuticals by 51.7% in the 1st quarter. Thompson Siegel & Walmsley LLC now owns 424,087 shares of the specialty pharmaceutical company’s stock worth $11,921,000 after acquiring an additional 144,533 shares during the period. Finally, Collective Family Office LLC lifted its position in shares of ANI Pharmaceuticals by 57.4% in the 1st quarter. Collective Family Office LLC now owns 8,225 shares of the specialty pharmaceutical company’s stock worth $231,000 after acquiring an additional 3,000 shares during the period. Institutional investors and hedge funds own 59.66% of the company’s stock.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $33.36 on Wednesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.79 and a quick ratio of 2.74. The company has a market capitalization of $575.46 million, a PE ratio of -7.36 and a beta of 1.05. ANI Pharmaceuticals, Inc. has a one year low of $22.31 and a one year high of $60.23. The business has a 50 day simple moving average of $29.76 and a 200 day simple moving average of $32.10.

ANI Pharmaceuticals (NASDAQ:ANIPGet Rating) last posted its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.22). ANI Pharmaceuticals had a positive return on equity of 6.66% and a negative net margin of 27.78%. The company had revenue of $64.48 million for the quarter, compared to the consensus estimate of $65.50 million. During the same quarter last year, the business earned $0.92 EPS. On average, sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 0.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, April 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $58.50.

ANI Pharmaceuticals Company Profile

(Get Rating)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.

Featured Stories

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIPGet Rating).

Receive News & Ratings for ANI Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ANI Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts